Soligenix Appoints Tomas J. Philipson as Strategic Advisor

Soligenix, a biopharmaceutical company, has appointed Tomas J. Philipson as a Strategic Advisor. Philipson is an expert in US economic and health care policy, frequently appearing on major media outlets. He currently serves as Managing Partner of MEDA Ventures, and has co-founded several companies, including Precision Health Economics LLC. His expertise and network will contribute to Soligenix's business and government affairs efforts.

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, has appointed Tomas J. Philipson, PhD, as a Strategic Advisor. Dr. Philipson brings extensive experience in U.S. economic policy, particularly health care policy, and a robust network in both government and business affairs.

Dr. Philipson is a prominent figure in the field of health economics, having served as Managing Partner of MEDA Ventures and co-founding several companies, including Precision Health Economics LLC. His government service includes roles as vice chairman and acting chairman of President Trump's White House Council of Economic Advisers from 2017 to 2020, and as a senior economic adviser to the heads of the U.S. Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS). His expertise in healthcare policy and economics will contribute to Soligenix's business and government affairs efforts, particularly as the company advances its lead product candidate, HyBryte™, through regulatory approval and commercialization.

HyBryte™, a novel photodynamic therapy using safe, visible light for activation, has shown promising results in treating cutaneous T-cell lymphoma (CTCL). The product has received orphan drug and fast track designations from the FDA, as well as orphan designation from the European Medicines Agency (EMA). In a Phase 3 clinical trial, HyBryte™ demonstrated significant efficacy and safety, with 49% of patients achieving a positive treatment response after 18 weeks of therapy.

Dr. Philipson's appointment is expected to provide strategic guidance and leverage his extensive network to support Soligenix's mission of developing and commercializing products for rare diseases. The company plans to work closely with Dr. Philipson as it progresses through the regulatory approval process for HyBryte™ and other pipeline programs.